Azenta(US:AZTA)2026-02-04 14:32Financial Data and Key Metrics Changes - Total revenue for Q1 2026 was $149 million, up 1% reported but down 1% organically, with a 2% headwind from foreign exchange [16][18] - Non-GAAP EPS for the first quarter was $0.09, and adjusted EBITDA margin was 8.5%, down approximately 230 basis points year-over-year [17][19] - Free cash flow for the quarter was $15 million, with cash, cash equivalents, and marketable securities totaling $571 million, an increase of $25 million quarter-over-quarter [17][18] Business Line Data and Key Metrics Changes - In Sample Management Solutions (SMS), revenue was $81 million, flat on a reported basis and down 2% organically, with growth in Biorepositories offset by declines in Automated Stores and Cryo [20][21] - Multiomics revenue was $67 million, up 1% reported and flat organically, with growth in Next-Generation Sequencing and Gene Synthesis, but continued weakness in Sanger Sequencing [21][22] Market Data and Key Metrics Changes - North America showed softness due to macro-driven budget constraints and a government shutdown, while Europe and Asia performed strongly, particularly with China showing 26% organic growth [22][74] - The overall market conditions remain mixed, with cautious capital spending decisions impacting bookings [9][10] Company Strategy and Development Direction - The company aims to embed operational excellence, accelerate growth, and expand margins as part of its turnaround strategy [8][10] - Focus on core portfolio and strategic capital deployment, including a $250 million share repurchase authorization [12][18] - The company is committed to a full-year 2026 guidance of 3%-5% organic revenue growth and adjusted EBITDA margin expansion of approximately 300 basis points [15][23] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about improvements in capital markets and M&A activity, expecting greater clarity around government and academic funding [9][10] - The company anticipates a transitional year for the life sciences sector, with expectations for acceleration in the second half of 2026 as delayed approvals are processed [10][15] Other Important Information - The sale of B Medical Systems is expected to close on or before March 31, 2026, further sharpening the company's focus on its core portfolio [12][16] - The company is addressing quality issues in Automated Stores, with remediation efforts expected to be completed by the end of Q2 [21][63] Q&A Session Summary Question: Can you talk about your level of confidence in getting the SMS margins back to where you want them to be? - Management acknowledged margin headwinds due to product and geographic mix but reiterated confidence in achieving guidance for the full year [25][28] Question: Can you characterize the conversations you've had with customers in the academic and government segments? - Management reported positive conversations and momentum in North America, with expectations for improvement in the back half of the year [32][33] Question: Can you talk about the level of comfort or visibility into key drivers for the second-half ramp? - Management expressed confidence in North America coming back, with growth investments in R&D and innovation expected to drive performance [36][37] Question: How are you thinking about performance in the U.S. academic market given flat NIH budgets? - Management noted a shift in funding towards larger projects and expressed optimism about supporting those programs [46][47] Question: What are you seeing from pharma and biotech customers right now? - Management indicated more clarity in the pharma and biotech markets, with ongoing investments and positive sentiment from customers [48][49] Question: Can you provide insight into the extra costs impacting gross margin? - Management detailed specific costs related to quality issues and lab inefficiencies, while emphasizing ongoing efforts to optimize margins [51][53]